Loading organizations...
TidalSense develops AI-driven diagnostic and monitoring technologies for respiratory conditions, aiming to transform patient outcomes. Its core product, N-Tidal® Diagnose, utilizes novel patented sensor technology to provide precise insights into lung physiology through rapid CO2 sampling. This medical device, cleared under EU MDR for COPD diagnosis, integrates with a cloud platform and AI to perform near-real-time geometric analysis of breath waveforms, delivering point-of-care diagnoses within minutes.
The company was founded in 2013 by Julian Carter, driven by an insight to create a paradigm shift in respiratory medicine through earlier, more accurate diagnoses. Headquartered in Cambridge, UK, TidalSense began with the mission to revolutionize population-level outcomes for patients by transforming traditional diagnostic pathways.
TidalSense’s product serves healthcare providers, including health systems, and pharmaceutical companies. The company’s vision is to achieve widespread pathway transformation by focusing on sustainable innovation that addresses the specific needs of both health systems and patients, ultimately working towards a future of improved respiratory health management.
TidalSense has raised $3.0M across 1 funding round.
TidalSense has raised $3.0M in total across 1 funding round.
TidalSense is a Cambridge-based respiratory technology company that builds AI-driven diagnostic and remote‑monitoring solutions for COPD and asthma using a patented fast-response CO2 sensor (N‑Tidal) and cloud-based algorithms[1][3]. The company’s flagship product, N‑Tidal Diagnose, is a point‑of‑care, non‑spirometry diagnostic device that analyses ~75 seconds of relaxed breathing to produce near‑real‑time diagnostic output for COPD and has received regulatory clearance under EU MDR as a Class IIa device[3][5].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
If you’d like, I can: provide a concise one‑page investor‑style summary, draft messaging for clinical partners, or pull key clinical evidence and trial endpoints referenced in TidalSense publications and press materials.
TidalSense has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in November 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2020 | $3M Seed | — | Ananda Impact Ventures, Business Growth Fund, Downing Ventures | Announced |
TidalSense has raised $3.0M in total across 1 funding round.
TidalSense's investors include Ananda Impact Ventures, Business Growth Fund, Downing Ventures.